Desjardins, A., Sampson, J. H., Peters, K. B., Vlahovic, G., Randazzo, D., Threatt, S., … Gromeier, M. (2015). Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination. In Journal of Clinical Oncology (Vol. 33, pp. 2068–2068). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2015.33.15_suppl.2068

Desjardins, Annick, John H. Sampson, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Stevie Threatt, James Emmett Herndon, et al. “Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.” In Journal of Clinical Oncology, 33:2068–2068. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2068.

Desjardins A, Sampson JH, Peters KB, Vlahovic G, Randazzo D, Threatt S, et al. Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 2068–2068.

Desjardins, Annick, et al. “Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.” Journal of Clinical Oncology, vol. 33, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2015, pp. 2068–2068. Crossref, doi:10.1200/jco.2015.33.15_suppl.2068.

Desjardins A, Sampson JH, Peters KB, Vlahovic G, Randazzo D, Threatt S, Herndon JE, Boulton S, Lally-Goss D, McSherry F, Lipp ES, Friedman AH, Friedman HS, Bigner DD, Gromeier M. Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 2068–2068.